The GLU test within the VITROS XT Chemistry Products GLU-Ca Slides quantitatively measures glucose (GLU) concentration in serum, plasma, urine, and cerebrospinal fluid using VITROS XT 7600 Integrated Systems. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders mellitus. neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

The Ca test within the VITROS XT Chemistry Products GLU-Ca Slides quantitatively measures calcium (Ca) concentration in serum, plasma, and urine using VITROS XT 7600 Integrated Systems. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms).

Special conditions for use statement: For prescription use only.

Device Description

The new device, the VITROS XT Chemistry Products GLU-Ca Slides is a single device that contains both a GLU test and a Ca test side by side separated by a plastic barrier sealed within a single slide frame. In this format, individual reactions occur and test results are generated for each analyte independently of the other analyte.

For glucose measurement, a drop of patient sample is deposited on the GLU test element of the slide and is evenly distributed by the spreading layer to the underlying layers. The oxidation of sample glucose is catalyzed by glucose oxidase to form hydrogen peroxide and gluconate. This reaction is followed by an oxidative coupling catalyzed by peroxidase in the presence of dye precursors to produce a dye. The intensity of the dye is measured by reflected light. The dye system used is closely related to that first reported by Trinder. ' The chemistry of the glucose slides has been described by Curme, et al.

For calcium measurement, a drop of patient sample is deposited on the Ca test element of the slide and is evenly distributed by the spreading layer to the underlying layers. The bound calcium is dissociated from binding proteins, allowing the calcium to penetrate through the spreading layer into the underlying reagent layer. There, the calcium forms a complex with Arsenazo III dye, causing a shift in the absorption maximum. After incubation, the reflection density of the colored complex is measured spectrophotometrically. The amount of colored complex formed is proportional to the calcium concentration in the sample.

AI/ML Overview

The provided document describes the analytical performance of the VITROS XT Chemistry Products GLU-Ca Slides for measuring Glucose (GLU) and Calcium (Ca) concentrations. Here's a breakdown of the requested information:

1. Acceptance Criteria and Reported Device Performance

The acceptance criteria are not explicitly stated as numerical targets in the document. Instead, the study aims to show substantial equivalence to predicate devices and acceptable performance based on established clinical laboratory guidelines (CLSI protocols). The "reported device performance" is summarized from the tables in the document.

Table of Acceptance Criteria (Implied by Study Design) and Reported Device Performance

Test Category	Implied Acceptance Criteria (via CLSI Protocols & Equivalence to Predicate)	Reported Device Performance (VITROS XT GLU-Ca Slides)
Method Comparison (Correlation with Predicate)	High correlation (e.g., slope near 1, intercept near 0, high correlation coefficient) to predicate devices.	GLU Serum (N=116): Slope 0.99, Intercept -0.91, Corr. Coeff. 1.000GLU Urine (N=103): Slope 1.01, Intercept -0.18, Corr. Coeff. 1.000GLU CSF (N=149): Slope 0.98, Intercept -0.06, Corr. Coeff. 1.000Ca Serum (N=112): Slope 0.99, Intercept 0.04, Corr. Coeff. 0.999Ca Urine (N=119): Slope 0.99, Intercept 0.07, Corr. Coeff. 0.999
Precision	Meeting CLSI EP05-A3 guidelines for repeatability, within-day, and within-lab precision. Generally, low CV% and SD values.	GLU Serum: CV% values ranging from 0.3-0.6% (Repeatability), 0.8-1.0% (Within Day), 0.9-1.2% (Within Lab)GLU Urine: CV% values ranging from 0.5-1.2% (Repeatability), 0.6-1.8% (Within Day), 0.6-1.9% (Within Lab)GLU CSF: CV% values ranging from 0.4-0.8% (Repeatability), 0.6-1.2% (Within Day), 0.6-1.2% (Within Lab)Ca Serum: CV% values ranging from 0.5-1.7% (Repeatability), 0.6-2.6% (Within Day), 0.9-2.9% (Within Lab)Ca Urine: CV% values ranging from 0.7-2.3% (Repeatability), 1.0-3.5% (Within Day), 1.1-3.4% (Within Lab)
Detection Limits (LoQ)	LoQ should meet pre-defined total error (TE) goals based on the Westgard model.	GLU Serum: Calculated LoQ 15.9 mg/dL (Claimed 20 mg/dL)GLU Urine: Calculated LoQ 13.0 mg/dL (Claimed 20 mg/dL)GLU CSF: Calculated LoQ 15.2 mg/dL (Claimed 20 mg/dL)Ca Serum: Calculated LoQ 0.49 mg/dL (Claimed 1.0 mg/dL)Ca Urine: Calculated LoQ 0.60 mg/dL (Claimed 1.0 mg/dL)
Linearity	The device should demonstrate linearity across its claimed measuring range.	GLU Serum/plasma: Linear range 19.3-635.3 mg/dL (Claimed 20-625 mg/dL)GLU Urine: Linear range 15.4-776.1 mg/dL (Claimed 20-650 mg/dL)GLU CSF: Linear range 19.2-650.9 mg/dL (Claimed 20-650 mg/dL)Ca Serum/plasma: Linear range 0.85-15.82 mg/dL (Claimed 1.0-14.0 mg/dL)Ca Urine: Linear range 0.75-20.67 mg/dL (Claimed 1.0-17.8 mg/dL)
Specificity (Interference)	Minimal or quantifiable interference from common substances at specified concentrations, maintaining bias within acceptable limits.	Identified specific interferents and their observed bias for GLU (Glutathione, Hemoglobin, Total Protein in serum; Ascorbic acid, Dextran, Hemoglobin, N-Acetylcysteine in urine; Hemoglobin in CSF) and Ca (Cefoxitin, Cholesterol, Gadodiamide, Hemoglobin, Sodium, Sorbitol, Total Protein in serum). No interference for many other tested substances (79 for GLU serum, 18 for GLU urine, 75 for Ca serum, 20 for Ca urine).

2. Sample Sizes Used for the Test Set and Data Provenance

Method Comparison:
- GLU Serum: N=116
- GLU Urine: N=103
- GLU CSF: N=149
- Ca Serum: N=112
- Ca Urine: N=119
Precision:
- GLU (Serum, Urine, CSF): 80 observations (2 replicates per run, 2 runs per day over 20 days) for each fluid type.
- Ca (Serum, Urine): 80 observations (2 replicates per run, 2 runs per day over 20 days) for each fluid type.
Detection Limits (LoQ, LOB, LOD): Not explicitly stated as a number of patient samples, but the determination was based on CLSI EP17-A2.
Linearity: Not explicitly stated as a number of patient samples, but involved "A series of twenty proportionally related admixtures of low and high test fluids" for each test and sample type, each tested in quadruplicate.
Specificity (Interference): Not explicitly stated as a number of patient samples. Involves testing of "substances" at specified concentrations in serum, urine, and CSF.

Data Provenance: The document does not specify the country of origin of the data. The studies are non-clinical analytical performance studies, which typically use well-characterized, banked samples or prepared control materials rather than 'retrospective' or 'prospective' patient data in the clinical sense. The samples for method comparison are referred to as "patient samples."

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This document describes the analytical performance of an in vitro diagnostic device. The "ground truth" here refers to the reference method measurements for Method Comparison studies or the known concentrations of control materials for Precision, Detection Limits, Linearity, and Specificity studies.

No human experts (e.g., radiologists) are involved in establishing ground truth for chemical analyte measurements.
The ground truth is established by the predicate devices (VITROS Chemistry Products GLU Slides and VITROS Chemistry Products Ca Slides on the VITROS 5600 Integrated System) for method comparison studies, and by the known values of patient pools and quality control materials for precision, detection limits, and linearity. For specificity, the ground truth is the known concentration of the interferent and the analyte in the prepared samples.

4. Adjudication Method for the Test Set

Not applicable. This is an analytical performance study for an in vitro diagnostic device, not a study involving human interpretation or adjudication of diagnostic findings.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No. This is an analytical performance study for an in vitro diagnostic device, not an MRMC study comparing human reader performance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, this entire document describes studies of the standalone performance of the VITROS XT Chemistry Products GLU-Ca Slides on the VITROS XT 7600 Integrated System. The performance metrics presented (method comparison, precision, linearity, detection limits, specificity) are all measures of the device's analytical capabilities without human intervention in the result generation or interpretation beyond operating the instrument and collecting the samples.

7. The Type of Ground Truth Used

Method Comparison: Ground truth was established by the predicate devices (VITROS Chemistry Products GLU Slides [K182072] and VITROS Chemistry Products Ca Slides [K072440]) run on the VITROS 5600 Integrated System.
Precision and Linearity: Ground truth was established by known concentrations of patient pools and quality control materials.
Detection Limits (LoQ/LOD/LOB): Ground truth was based on the known concentrations of prepared samples and determined using statistical methods compliant with CLSI EP17-A2.
Specificity (Interference): Ground truth was based on the known concentrations of the target analyte and the potential interfering substances in prepared samples.

8. The Sample Size for the Training Set

Not applicable. This document describes an analytical validation, not a machine learning study that typically involves "training sets." The device is a chemistry analyzer system, not an AI algorithm that learns from data.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no "training set" in the context of this device's validation.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the agency's name, "U.S. Food & Drug Administration."

April 3, 2019

Ortho-Clinical Diagnostics, Inc. Darlene Phillips Manager, Regulatory Affairs 100 Indigo Creek Drive Rochester, NY 14626

Re: K190520

Trade/Device Name: VITROS XT Chemistry Products GLU-Ca Slides Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: CGA, CJY Dated: February 28, 2019 Received: March 4, 2019

Dear Darlene Phillips:

We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to Mav 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Kellie B. Kelm -S

for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K190520

Device Name VITROS XT Chemistry Products GLU-Ca Slides

Indications for Use (Describe)

For in vitro diagnostic use only

Special conditions for use statement: For prescription use only.

Type of Use (Select one or both, as applicable)|X Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: K190520

Submitter's Information

Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, New York 14626-5101 Phone: (585) 453-4253 Fax: (585) 453-3113

Contact Person:

Darlene J Phillips, RAC Manager, Regulatory Affairs

Date of Preparation: February 28, 2019

Device Proprietary Name(s):

VITROS XT Chemistry Products GLU-Ca Slides

Common Names:

Glucose test Calcium test

Classification Names

Test	ProductCode	Class	Regulation Section	Panel
GLU	CGA	Class II	21 CFR 862. 1345 Glucose test system	Clinical
Ca	CJY	Class II	21 CFR 862. 1145 Calcium test system	Chemistry(75)

Predicate Device(s)

Predicate Devices	FDA 510(k) Number
VITROS Chemistry Products GLU Slides	K182072
VITROS Chemistry Products Ca Slides	K072440

{4}------------------------------------------------

Intended Use Statement(s) VITROS XT Chemistry Products GLU-Ca Slides

Rx Only. For in vitro diagnostic use only.

The GLU test within the VITROS XT Chemistry Products GLU-Ca Slides quantitatively measures glucose (GLU) concentration in serum, plasma, urine, and cerebrospinal fluid using VITROS XT 7600 Integrated Systems. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

The Ca test within the VITROS XT Chemistry Products GLU-Ca Slides quantitatively measures calcium (Ca) concentration in serum. plasma, and urine using VITROS XT 7600 Integrated Systems. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms).

Device Description

Trinder P. Determination of Glucose in Blood Using Glucose Oxidase with an l Alternative Oxygen Receptor. Ann. Clin. Biochem. 6:24; 1969.

Curme HG. et al. Multilayer Film Elements for Clinical Analysis. Clin. Chem. 2. 24:1335—1342; 1978.

{5}------------------------------------------------

Comparison to Predicate Devices

The following tables show similarities and differences between the new and predicate devices.

Summary of the technological characteristics of the device compared to thepredicate device
DeviceCharacteristic	New DeviceVITROS XT GLU-Ca Slide(New)	Predícate DevicesVITROS GLU Slide [K182072]VITROS Ca Slide [K072440](Current)
Intended Use	Same for each individual testFor in vitro diagnostic use only.The GLU test within the VITROSXT Chemistry Products GLU-Ca Slides quantitativelymeasures glucose (GLU)concentration in serum, plasma,urine, and cerebrospinal fluid(CSF).The Ca test within the VITROSXT Chemistry ProductsGLU-Ca Slides quantitativelymeasures calcium (Ca)concentration in serum,plasma, and urine.	For in vitro diagnostic use only.VITROS Chemistry Products GLUSlides quantitatively measureglucose (GLU) concentration inserum, plasma, urine, and CSF.VITROS Chemistry Products CaSlides quantitatively measurecalcium (Ca) concentration inserum, plasma, and urine.
DeviceDescription	No Change	Multilayered, analytical elementcoated on a polyester support
Basic Principle	No Change	GLU ColorimetricCa Colorimetric
Incubation timeand temperature	No Change	Approximately 5 minutes37°C (98.6° F)
Sample type	No Change	GLU Serum, plasma, urine andcerebrospinal fluid (CSF)Ca Serum, plasma and urine
Amount of SlideReactiveIngredients percm² (test)	No ChangeThe composition of the analyticalelement of each test within theVITROS XT Slide will remainthe same as that used in eachpredicate device	GLU Glucose oxidase (Aspergillus sp.)0.77 U; peroxidase (horseradishroot) 3.6 U; 1,7-dihydroxynaphthalene (dyeprecursor) 67 µg and 4-aminoantipyrine hydrochloride(dye precursor) 0.11 mg.Ca Arsenazo III dye 60 ug
Summary of the technological characteristics of the device compared to thepredicate device
DeviceCharacteristic	New DeviceVITROS XT GLU-Ca Slide(New)	Predícate DevicesVITROS GLU Slide [K182072]VITROS Ca Slide [K072440](Current)
Assay Range	No Change	GLU (mg/dL)Serum/plasma 20 - 625Urine 20 - 650CSF 20 - 650Ca (mg/dL)Serum/plasma 1.0 - 14.0Urine 1.0 – 17.8
Calibrators	Same	VITROS Chemistry ProductsCalibrator Kit 1
Controls	Same	VITROS Chemistry ProductsPerformance Verifier I and IIVITROS Chemistry Products LiquidPerformance Verifier I and II
Differences
Instrumentation	VITROS XT 7600 IntegratedSystem	VITROS 250/350, 5,1 FS and 4600Chemistry SystemsVITROS 5600 and XT 7600

Summary of the technological characteristics of the device compared to the

{6}------------------------------------------------

Integrated Systems

GLU

6 µL

10 µL

વ...

Non-Clinical Testing Analytical Performance

GLU

Method Comparison

Sample volume

Method Comparison testing followed CLSI Protocol EP09c. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. Serum, urine and cerebrospinal fluid (glucose only) samples were evaluated on the VITROS XT Chemistry Products GLU-Ca Slides using the VITROS XT 7600 Integrated System and on VITROS Chemistry Products GLU Slides and VITROS Chemistry Products Ca Slides using the VITROS 5600 Integrated System. The correlation between the predicate and the new tests within the VITROS XT GLU-Ca Slides on the VITROS XT 7600 Integrated System is summarized below.

2.7 µL

3.5 µL

Weighted Deming regressions were performed to determine the correlation for GLU (all fluid types) and Ca (urine). Ordinary Deming regression was performed to determine the correlation between the Ca serum methods.

{7}------------------------------------------------

Summary of Method Comparison Regression Analysis DataUnits mg/dL
Test	N	Slope	Intercept	Corr. Coeff.	Test Range	Measuring range
GLU Serum	116	0.99	-0.91	1.000	25 - 571	20 - 625
GLU Urine	103	1.01	-0.18	1.000	24-642	20 - 650
GLU CSF	149	0.98	-0.06	1.000	21-596	20 - 650
Ca Serum	112	0.99	0.04	0.999	1.4-13.9	1.0 - 14.0
Ca Urine	119	0.99	0.07	0.999	2.2-17.2	1.0 - 17.8

Precision

Precision was evaluated with patient pools and quality control materials following CLSI Protocol EP05-A3, Evaluation of Precision Performance of Quantitative Methods; Approved Guideline-Third Edition, using the VITROS XT Chemistry Products GLU-Ca Slides on the VITROS XT 7600 Integrated System. The test included 80 observations (2 replicates per run, 2 runs per day over 20 days) for serum and urine for the Ca test and serum, urine, and CSF for the GLU test. The long term precision analysis is summarized below.

The data presented are a representation of test performance and are provided as a guideline. Variables such as sample handling and storage, reagent handling and storage, laboratory environment, and system maintenance can affect reproducibility of test results.

GLU Serum Units (mg/dL)
Mean	Repeatability*		Within Day**		Within Lab***		No. of	No. of
Conc.	SD	CV%	SD	CV%	SD	CV%	Obs.	Days
42	0.3	0.6	0.4	1.0	0.4	1.0	80	20
87	0.4	0.4	0.8	0.9	0.8	0.9	80	20
105	0.5	0.4	1.0	0.9	1.0	0.9	80	20
121	0.6	0.5	1.3	1.1	1.4	1.2	80	20
292	0.9	0.3	2.4	0.8	2.6	0.9	80	20
573	2.0	0.4	5.0	0.9	5.3	0.9	80	20
GLU Urine Units (mg/dL)
Mean	Repeatability*		Within Day**		Within Lab***		No. of	No. of
Conc.	SD	CV%	SD	CV%	SD	CV%	Obs.	Days
26	0.3	1.2	0.5	1.8	0.5	1.9	80	20
43	0.3	0.7	0.4	1.0	0.5	1.1	80	20
44	0.4	0.8	0.5	1.0	0.5	1.1	80	20
114	0.5	0.5	0.7	0.6	0.7	0.6	80	20
292	1.5	0.5	1.7	0.6	1.7	0.6	80	20

{8}------------------------------------------------

GLU CSF Units (mg/dL)
MeanConc.	Repeatability*SD	CV%	Within Day**SD	CV%	Within Lab***SD	CV%	No. ofObs.	No. ofDays
37	0.3	0.8	0.4	1.1	0.4	1.1	80	20
38	0.3	0.8	0.5	1.2	0.5	1.2	80	20
39	0.3	0.7	0.4	1.1	0.5	1.2	80	20
87	0.4	0.4	0.6	0.7	0.6	0.7	80	20
318	1.4	0.4	1.7	0.6	2.0	0.6	80	20
644	2.7	0.4	3.5	0.6	3.6	0.6	80	20
Ca Serum Units (mg/dL)
MeanConc.	Repeatability*SD	CV%	Within Day**SD	CV%	Within Lab***SD	CV%	No. ofObs.	No. ofDays
2.3	0.04	1.7	0.06	2.6	0.07	2.9	80	20
6.8	0.04	0.6	0.06	0.8	0.09	1.4	80	20
8.4	0.07	0.8	0.08	0.9	0.10	1.2	80	20
8.8	0.05	0.6	0.07	0.8	0.08	0.9	80	20
11.9	0.07	0.6	0.08	0.7	0.11	1.0	80	20
12.2	0.06	0.5	0.07	0.6	0.11	0.9	80	20
Ca UrineUnits (mg/dL)
MeanConc.	Repeatability*SD	CV%	Within Day**SD	CV%	Within Lab***SD	CV%	No. ofObs.	No. ofDays
2.1	0.05	2.3	0.07	3.5	0.07	3.4	80	20
5.0	0.04	0.7	0.05	1.0	0.06	1.1	80	20
5.6	0.05	0.8	0.06	1.1	0.07	1.2	80	20
6.6	0.04	0.6	0.07	1.1	0.09	1.3	80	20
9.7	0.08	0.8	0.08	0.8	0.10	1.1	80	20
15.7	0.11	0.7	0.16	1.0	0.28	1.8	80	20

*Repeatability (formerly called within-run precision) was determined using two replicates per run.

**Within Day precision was determined using two runs/day with two replications per run

***Within Lab precision was determined using a single lot of slides and a single calibration

Detection Limits

Detection capability studies for the GLU and Ca tests within the VITROS XT GLU-Ca Slides were evaluated according to CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures.

{9}------------------------------------------------

LoQ determination was set on pre-defined total error (TE) goals based on the Westgard model, a combination of bias and precision. The Total Error goal used to accept the LoO for GLU was ≤ 4.8 mg/dL for serum, ≤ 3.9 mg/dL for urine and ≤ 4.6 mg/dL for CSF. The Total Error goal used to accept the LoQ for Ca was ≤ 0.15 mg/dL for serum and ≤ 0.42 mg/dL for urine.

	GLU (mg/dL)			Ca (mg/dL)
	Serum	Urine	CSF	Serum	Urine
LOB	1.0	2.5	1.0	0.10	0.05
LOD	1.9	3.0	1.9	0.14	0.09
LOQ	15.9	13.0	15.2	0.49	0.60
Claimed LOQ	20	20	20	1.0	1.0

The results of this analysis are summarized below:

Linearitv

Linearity studies were performed according to CLSI EP06-A, Evaluation of the Linearity of Ouantitative Measurement Procedures: A Statistical Approved Guideline (2003). VITROS XT GLU-Ca Slides were tested on the VITROS XT 7600 Integrated System. A series of twenty proportionally related admixtures of low and high test fluids were tested to verify linearity of the GLU and Ca serum and urine tests and the GLU CSF test; each sample was tested in quadruplicate. The linearity studies support the claimed measuring ranges for the individual tests within the VITROS XT GLU-Ca Slides.

Assay	Fluid	Measuring Range(mg/dL)	Linear Range(mg/dL)
GLU	Serum/plasma	20-625	19.3-635.3
	Urine	20-650	15.4-776.1
	CSF	20-650	19.2-650.9
Ca	Serum/plasma	1.0-14.0	0.85-15.82
	Urine	1.0-17.8	0.75-20.67

Serum and plasma samples with values greater than the measuring range may be diluted with one part sample to one part diluent. A 7% BSA solution was found to be an acceptable diluent for the GLU test within the VITROS XT Chemistry Products GLU-Ca Slides. Isotonic saline and reagent-grade water were found to be acceptable diluents for the Ca test within the VITROS XT Chemistry Products GLU-Ca Slides.

Urine samples with values greater than the measuring range may be diluted with one part sample to one part diluent. Isotonic saline and reagent-grade water were found to be acceptable diluents for the GLU test within the VITROS XT Chemistry Products GLU-Ca Slides. Reagent-grade water was found to be an acceptable diluent for the Ca test within the VITROS XT Chemistry Products GLU-Ca Slides.

Expected Values

The expected values of the GLU and Ca tests within the VITROS XT GLU-Ca Slides are the not changed from those of the predicate assays. Each laboratory should confirm the validity of these intervals for the population it serves.

{10}------------------------------------------------

GLU Reference Interval

GLU reference intervals for serum, urine and CSF are based on external studies 1.

GLU Test Expected Values
Serum
Fasting adults	74-100 mg/dL
Urine
Random	1-15 mg/dL
24 hour	< 500 mg/day*
CSF	40-70 mg/dL

Glucose concentration (mg/dL) x 24-hour volume (dL) = mg/day.

Ca Reference Interval

Ca reference intervals are based on external studies for serum and urine .

Ca Test Expected Values
Serum	8.6-10.3 mg/dL
Urine - Dietary Ca Intake:
Ca-free	5-40 mg/day*
Low to average	50-150 mg/day*
Average	100-300 mg/day*

Calcium concentration (mg/dL) x 24-hour volume (dL) = mg/day.

Each laboratory should confirm the validity of these intervals for the population it serves.

References

Tietz NW. Fundamentals of Clinical Chemistry and Molecular Diagnostics. 7ª ed. St. Louis: Elsevier; 2015.
Tietz NW (ed). Fundamentals of Clinical Chemistry. ed. 5. Philadelphia: WB Saunders; 968; 2001.

Specificity

The GLU and Ca tests within the VITROS XT Chemistry Products GLU-Ca Slides were screened for interfering substances following CLSI document EP07, Interference Testing in Clinical Chemistry. The supplemental tables in CLSI document EP37 were referenced for recommended testing concentrations for analytes and endogenous substances that may interfere in clinical chemistry measurement procedures.

Point estimates of the effects of potential interferents on VITROS XT GLU-Ca Slides were made using the paired difference method. Dose-response analysis was conducted to characterize the degree of interference for each substance that interfered at the initial EP37 level screening test, and expected bias was reported at the lowest test level which did not meet acceptance criteria for bias as shown in the product claims.

{11}------------------------------------------------

GLU Test

For the GLU test within VITROS XT GLU-Ca Slides, interference was observed for three (3) substances with serum. The substances listed in the table, when tested at the concentrations indicated, caused the bias shown. The bias is an estimate of the maximum bias observed.

It is possible that other interfering substances may be encountered. These results are representative; however, your results may differ somewhat due to test-to-test variation. The degree of interference at concentrations other than those listed might not be predictable.

GLU Serum Known Interfering Substances
Interferent	InterferentConcentration	GlucoseConcentration(mg/dL)	Bias(mg/dL)
Glutathione	92 mg/dL	73	-10.4
Hemoglobin	1000 mg/dL	79	7.6
Total Protein	15 g/dL	74	8.8
		217	20.4

. When using samples with visible hemolysis (Hb > 200 mg/dL), there may be a negative bias due to catalase released from the lysis of red blood cells. The VITROS XT Systems can perform Sample Indices using the MicroSensor module, and the GLU result from samples with visible hemolysis will be flagged with H (Hemolysis).
Elevated lipids may limit diffusion of oxygen to the reactants. Dilute grossly lipemic samples twofold before analysis.

Interference was observed with four (4) substances tested in urine.

GLU Urine Known Interfering Substances
Interferent	InterferentConcentration	GlucoseConcentration(mg/dL)	Bias(mg/dL)
Ascorbic acid	50 mg/dL	31	-14.0
Ascorbic acid	13 mg/dL	171	-13.7
Dextran	7.5 g/dL	31	8.0
Dextran	2.5 g/dL	169	14.4
Hemoglobin	250 mg/dL	33	8.5
N-Acetylcysteine	25 mg/dL	166	-14.0

{12}------------------------------------------------

GLU CSF Known Interfering Substances
Interferent	InterferentConcentration	Glucose Concentration(mg/dL)	Bias(mg/dL)
Hemoglobin	250 mg/dL	47	5.0
Hemoglobin	1000 mg/dL	69	12.1
Hemoglobin	1000 mg/dL	87	10.2

One (1) substance was tested and found to cause interference in cerebrospinal fluid (CSF).

For the GLU test within VITROS XT GLU-Ca Slides, no interference was observed for seventy-nine (79) substances tested in serum, bias < 7.0 mg/dL at approximately 80 mg/dL glucose and bias < 14 mg/dL at approximately 200 mg/dL glucose. No interference was observed for eighteen (18) substances tested in urine, bias < 7.0 mg/dL at approximately 30 mg/dL glucose and bias < 11.9 mg/dL at approximately 170 mg/dL glucose.

Ca Test

For the Ca test within VITROS XT GLU-Ca Slides, interference was observed for seven (7) substances with serum. The substances listed in the table, when tested at the concentrations indicated, caused the bias shown. The bias is an estimate of the maximum bias observed.

Ca Serum Known Interfering Substances
Interferent	InterferentConcentration	Calcium Concentration(mg/dL)	Bias(mg/dL)
Cefoxitin	663 mg/dL	7.7	0.28
Cefoxitin	663 mg/dL	11.3	0.50
Cholesterol	525 mg/dL	6.3	0.34
Cholesterol	625 mg/dL	9.5	0.34
Gadodiamide	86 mg/dL	7.4	0.35
Hemoglobin	1000 mg/dL	8.3	-0.30
Sodium	391 mg/dL	7.4	0.35
Sodium	391 mg/dL	11.1	0.52
Sorbitol	1800 mg/dL	11.9	-0.37
Total Protein	15 g/dL	12.1	-0.45

For the Ca test within VITROS XT GLU-Ca Slides, no interfering compounds were observed for urine. For the Ca test within VITROS XT GLU-Ca Slides, no interference was observed for seventy-five (75) substances tested in serum, bias < 0.23 mg/dL at approximately 8 mg/dL calcium and bias < 0.27 mg/dL at approximately 12 mg/dL calcium. No interference was observed for twenty (20) substances tested in urine, bias < 0.79 mg/dL at approximately 5 mg/dL calcium and bias < 1.2 mg/dL at approximately 12 mg/dL calcium.

{13}------------------------------------------------

Other Limitations

Keeping the sample in an open container at room temperature may increase the reported calcium concentration by up to 0.4 mg/dL. Changes are due to the loss of carbon dioxide, which results in an increase in pH of the specimen. The increase in pH is minimized by anaerobic handling procedures followed by prompt analysis. Adherence to these procedures is especially important for pediatric samples where the sample volume is small. Certain drugs and clinical conditions are known to alter glucose and calcium concentrations in vivo. For additional information, refer to one of the published summaries.

Conclusion

The conclusions drawn from the nonclinical tests (discussed above) demonstrate the VITROS XT Chemistry Products GLU-Ca Slides for use on the VITROS XT 7600 Integrated System are as safe, effective, and perform as well as the predicate devices. The information submitted in the premarket notification is complete and supports a substantial equivalence decision.

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.